Association and interaction between vitamin D level and metabolic syndrome for non-alcoholic fatty liver disease

Bennouar, Salam; Cherif, A. Bachir; Kessira, Amel; Bennouar, Djamel Eddine; Abdi, Samia

doi:10.1007/s40200-021-00857-5

Cited by 9 publications

(6 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, the NAFLD patients had higher BMI, WC, SBP, DBP, hepatic dysfunction, glucose metabolic disorder, and lipid metabolic disorder with a high prevalence of diabetes, hypertension, overweight, and obesity, which are related to metabolic syndromes ( 68 – 70 ). Previous studies reported lower serum 25(OH)D 3 in Europeans and patients from southeast China than in controls ( 53 , 55 ). A previous meta-analysis based on a large population reported an inverse correlation between serum 25(OH)D 3 and NAFLD in European individuals ( 71 ).…”

Section: Discussionmentioning

confidence: 76%

“…Based on an FLI cutoff of 60, the cases were divided into the following two groups: no fatty liver (FLI <60) and fatty liver (FLI≥60). ( 55 ).…”

Section: Methodsmentioning

confidence: 99%

“…The FLI was calculated using the following equation: FLI = (e 0.953×ln(TG) + 0.139×BMI + 0.718 × ln(gGT) + 0.053 × WC -15.745 )/(1 + e 0.953×ln(TG) + 0.139×BMI + 0.718 × ln(gGT) + 0.053 × WC -15.745 ) × 100. The cases were individually divided into the following two groups based on the NFS and FIB-4: no advanced fibrosis (NFS<-1.455 or FIB-4<1.30) and fibrosis (NFS≥-1.455 or FIB-4≥1.30) (53,54). Based on an FLI cutoff of 60, the cases were divided into the following two groups: no fatty liver (FLI <60) and fatty liver (FLI≥60).…”

Section: Identification Of Hepatic Fibrosis and Hepatic Steatosismentioning

confidence: 99%

See 2 more Smart Citations

Vitamin D improves hepatic steatosis in NAFLD via regulation of fatty acid uptake and β-oxidation

Lian

Zhang

et al. 2023

Front. Endocrinol.

View full text Add to dashboard Cite

IntroductionThe study aimed to explore the association of serum 25(OH)D3 and hepatic steatosis in non-alcoholic fatty liver disease (NAFLD) patients and to determine whether the effect of vitamin D (VD) is mediated by activation of the peroxisome proliferator-activated receptor α (PPARα) pathway.MethodsThe study contained a case-control study, in vivo and in vitro experiments. A case-control study was conducted to compare serum parameters between NAFLD patients and controls and to evaluate the association of 25(OH)D3 and NAFLD. In vivo study, male Wistar rats were randomly divided into control and model groups, fed a standard chow diet and a high-fat diet (HFD), respectively, for 7 weeks to generate an NAFLD model. Then, the rats were treated with VD and a PPARα antagonist (MK886) for 7 weeks. Tissue and serum were collected and assessed by biochemical assays, morphological analysis, histological analysis, and western blot analysis. In vitro, HepG2 cells were incubated with oleic acid (OA) to induce steatosis, which was evaluated by staining. HepG2 cells were pretreated with MK886 followed by calcitriol treatment, and differences in lipid metabolism-related proteins were detected by western blot.ResultsNAFLD patients were characterized by impaired liver function, dyslipidemia, and insulin resistance. Serum 25(OH)D3 was negatively associated with alanine aminotransferase (ALT) in NAFLD. VD deficiency was a risk factor for patients with no advanced fibrosis. Adequate VD status (25(OH)D3 >20 ng/mL) had a protective effect in patients after adjustment for confounding variables. NAFLD rats showed hyperlipidemia with severe hepatic steatosis, systematic inflammation, and lower serum 25(OH)D3. VD treatment ameliorated hepatic steatosis both in NAFLD rats and OA-induced HepG2 cells. Further, MK886 inhibited the anti-steatosis effect of VD.ConclusionThe study revealed that an adequate VD level may act as a protective factor in NAFLD and that VD may alleviate hepatic steatosis via the PPARα signaling pathway.

show abstract

Section: Discussionmentioning

confidence: 76%

“…Based on an FLI cutoff of 60, the cases were divided into the following two groups: no fatty liver (FLI <60) and fatty liver (FLI≥60). ( 55 ).…”

Section: Methodsmentioning

confidence: 99%

Section: Identification Of Hepatic Fibrosis and Hepatic Steatosismentioning

confidence: 99%

See 1 more Smart Citation

Vitamin D improves hepatic steatosis in NAFLD via regulation of fatty acid uptake and β-oxidation

Lian

Zhang

et al. 2023

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

“…Two cross-sectional studies conducted on the elderly reported that subjects who were hypovitaminosis D had a higher prevalence of MetSyn as compared to those who were vitamin D sufficient [10,15]. In disease-specific populations such as persons with non-alcoholic fatty liver disease, psychotic disorders, and systemic lupus erythematosus, low serum vitamin D was associated with MetSyn [43][44][45]. A significant association was observed in a dose-response fashion in a meta-analysis study based on cross-sectional studies.…”

Section: Vitamin D and Cardiometabolic Diseases: Evidence From Epidem...mentioning

confidence: 99%

Vitamin D, Gut Microbiota, and Cardiometabolic Diseases—A Possible Three-Way Axis

Sukik

Alalwani

Ganji

2023

IJMS

View full text Add to dashboard Cite

Metabolic syndrome (MetSyn) is a precursor for several cardiometabolic diseases such as obesity, type-2 diabetes mellitus (T2DM), and cardiovascular diseases. Emerging evidence suggests that vitamin D deficiency links to cardiometabolic diseases through microbiota. A combination of poor vitamin D status and dysbiosis may contribute to the progression of cardiometabolic diseases. Therefore, in this review, we present the relationship among vitamin D, microbiota, and cardiometabolic diseases with a focus on MetSyn. We searched major databases for reports on vitamin D, microbiota, and MetSyn until June 2022. We reviewed 13 reports on the relation between vitamin D and MetSyn (6 randomized controlled and 7 cross-sectional studies) and 6 reports on the effect of vitamin D on the gut microbiome. Adequate vitamin D status has a beneficial effect on gut microbiota, therefore preventing the progression of MetSyn. Further, well-controlled studies are needed for a better understanding of the mechanisms of action involving vitamin D and microbiota in the pathogenesis of cardiometabolic diseases.

show abstract

“…Low vitamin D levels have been associated with insulin resistance-related diseases, such as diabetes, metabolic syndrome, and MAFLD [ 73 ]. Two recent cross-sectional studies showed that Vitamin D deficiency is associated with a higher risk of steatosis, represented by the Fatty Liver Index (FLI) score in obese patients [ 74 ]; in women, this association persists regardless of metabolic profile and body weight [ 75 ]. A retrospective cohort study shows that higher serum vitamin D levels were associated with a decreased risk of controlled attenuation parameter (CAP)-defined NAFLD, compared to low levels of serum vitamin D [ 76 ].…”

Section: Vitamin D In the Chronic Liver Diseasesmentioning

confidence: 99%

Role of Vitamin D in Liver Disease and Complications of Advanced Chronic Liver Disease

Ravaioli

Pivetti

Marco

et al. 2022

IJMS

View full text Add to dashboard Cite

Vitamin D is a crucial nutrient with many pleiotropic effects on health and various chronic diseases. The purpose of this review is to provide a detailed report on the pathophysiological mechanisms underlying vitamin D deficiency in patients with chronic liver disease, addressing the different liver etiologies and the condition of advanced chronic liver disease (cirrhosis) with related complications. To date, patients with liver disease, regardless of underlying etiology, have been shown to have reduced levels of vitamin D. There is also evidence of the predictive role of vitamin D values in complications and progression of advanced disease. However, specific indications of vitamin D supplementation are not conclusive concerning what is already recommended in the general population. Future studies should make an effort to unify and validate the role of vitamin D supplementation in chronic liver disease.

show abstract

Association and interaction between vitamin D level and metabolic syndrome for non-alcoholic fatty liver disease

Cited by 9 publications

References 29 publications

Vitamin D improves hepatic steatosis in NAFLD via regulation of fatty acid uptake and β-oxidation

Vitamin D improves hepatic steatosis in NAFLD via regulation of fatty acid uptake and β-oxidation

Vitamin D, Gut Microbiota, and Cardiometabolic Diseases—A Possible Three-Way Axis

Role of Vitamin D in Liver Disease and Complications of Advanced Chronic Liver Disease

Contact Info

Product

Resources

About